Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Plain-language summary
This trial is testing golidocitinib, a JAK1 inhibitor taken as a daily pill, against a placebo as maintenance therapy for patients with peripheral T-cell lymphoma who achieved a response after first-line chemotherapy and are not candidates for or have declined stem cell transplant. It is open to patients with PTCL-NOS, AITL, ALK-positive ALCL, or follicular T-cell lymphoma. Patients are randomly assigned to golidocitinib or placebo, and neither patients nor doctors know which they are receiving. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
PET-CTandct- DNAdetection (DEVICE): The patients who achieved CMR by PET-CT and MRD-neg by ct-DNA testing were evaluated at 12 months,One patient stopped maintenance treatment, while the rest continued for one year. | golidocitinib (DRUG): golidocitinib maintenance treatment given orally as 150mg every other day | Placebo (DRUG): Placebo given orally as 150mg every other day
PET-CTandct- DNAdetection, golidocitinib, Placebo
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details